My Cart

Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8)

Customer Reviews
Cat. No. / Size
Price
Qty
HGS-S249-20ul
$130.00
HGS-S249-100ul
$440.00
ETA of in-stock products:2 business days
Sub-Total$ 0

Product Details

  • Background

    Recombinant Monoclonal Anti-CD45RO Antibody, Mouse (4C8) is a CD45RO primary antibody for IHC application. CD45RO (UCHL1, ubiquitin carboxyl terminal esterase L1) is the shortest isoform of a receptor-type protein tyrosine phosphatase, CD45 glycoprotein. CD45 is crucial in lymphocyte development and antigen signaling, serving as an important regulator of Src-family kinases, promotes cell survival by modulating integrin-mediated signal transduction pathway and is also involved in DNA fragmentation during apoptosis.

  • Product Specifications

    Host Species
    Mouse
    Isotype
    Mouse IgG
    Clone
    4C8
    Application
    IHC-P
    Dilution Ratio
    1: 200 - 1: 1000
    Form
    Liquid
    Clonality
    Monoclonal
    Reactivity
    Human
    Synonyms
    CD45RO
    Concentration
    0.9~1.1 mg/ml
    Specificity
    React with CD45RO protein on the membrane of target cell/tissue
    Purification Tech
    Protein A
    Preservation
    Tris buffer, 1% BSA
  • Experiment Protocol

    LEICA Experiment Protocol

  • Storage

    Shipped at 4°C, Blue Ice. Store at +4°C for short term (1-2 weeks). Store at -20°C for long term.
    Avoid freeze / thaw cycle. Upon delivery aliquot. The shelf life is 30 days from the date of opening.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • Sample Staining Data

     CD45RO SAMPLE STAINING DATA
  •  CD45RO SAMPLE STAINING DATA
  •  CD45RO SAMPLE STAINING DATA

    Immunohistochemical analysis of paraffin embedded human cancer tissue labelled with HGS-S249 at 1/500 dilution.
    Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.

Customer Reviews
Writing Reviews

Recent Advances

 
Drug Development Progress
  • English Name:

    Leukocyte common antigen

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    4 Details

  • Highest Development Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews